Epidermal growth factor receptor-tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung: A meta-analysis

Asia-Pacific Journal of Clinical Oncology

Volumn 10, Issue 3, 2014, Pages 273-278

  Ameratunga, Malaka ^a   Pavlakis, Nick ^c   Gebski, Val ^d   Broad, Adam ^a   Khasraw, Mustafa ^a,b,d  

^a Andrew Love Cancer Centre   (Australia)

^b DEAKIN UNIVERSITY   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Epidermal growth factor (EGFR) inhibitor; Lung cancer; Meta analysis; Squamous cell carcinoma; Tyrosine kinase inhibitor (TKI)

Indexed keywords

AFATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; PLACEBO; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CAUCASIAN; DRUG EFFICACY; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THERAPY EFFECT; ANTAGONISTS AND INHIBITORS; CARCINOMA, SQUAMOUS CELL; ENZYMOLOGY; LUNG NEOPLASMS; META ANALYSIS; PROGNOSIS;

CARCINOMA, SQUAMOUS CELL; HUMANS; LUNG NEOPLASMS; PROGNOSIS; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84906079525     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/ajco.12231     Document Type: Article

References (29)

1. Fukuoka M, Wu Y-L, Thongprasert S etal. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011; 29: 2866-2874.
2. Lynch TJ, Bell DW, Sordella R etal. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
3. Shepherd FA, Rodrigues Pereira J, Ciuleanu T etal. Erlotinib in previously treated non-small-cell lung cancer. NEJM 2005; 353: 123-132.
4. Zhou C, Wu YL, Chen G etal. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735-742.
5. Cappuzzo F, Ciuleanu T, Stelmakh L etal. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010; 11: 521-529.
6. Keedy VL, Temin S, Somerfield MR etal. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011; 29: 2121-2127.
7. Buettner R, Wolf J, Thomas RK. Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment. J Clin Oncol 2013; 31: 1858-1865.
8. Laurie SA, Goss GD. Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non-small-cell lung cancer. J Clin Oncol 2013; 31: 1061-1069.
9. Hirsch FR, Varella-Garcia M, Bunn PA etal. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006; 24: 5034-5042.
10. Thatcher N, Chang A, Parikh P etal. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 1527-1537.
11. Tsao M-S, Sakurada A, Cutz J-C etal. Erlotinib in lung cancer - molecular and clinical predictors of outcome. NEJM 2005; 353: 133-144.
12. Zhu CQ, da Cunha Santos G, Ding K etal. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; 26: 4268-4275.
13. Gelsomino F, Agustoni F, Niger M, Valota M, Haspinger ER. Epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with EGFR wild-type non-small-cell lung cancer: the never-ending story. J Clin Oncol 2013; 31: 3291-3293.
14. Marchetti A, Martella C, Felicioni L etal. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005; 23: 857-865.
15. Jänne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 2005; 23: 3227-3234.
16. Lee CK, Brown C, Gralla RJ etal. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst 2013; 105: 595-605.
17. Chen X, Liu Y, Roe OD etal. Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review. PLoS ONE 2013; 8: e59314.
18. Lee SM, Khan I, Upadhyay S etal. First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2012; 13: 1161-1170.
19. Perol M, Chouaid C, Perol D etal. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2012; 30: 3516-3524.
20. Zhang L, Ma S, Song X etal. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol 2012; 13: 466-475.
21. Gaafar RM, Surmont VF, Scagliotti GV etal. A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). Eur J Cancer 2011; 47: 2331-2340.
22. Goss G, Ferry D, Wierzbicki R etal. Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status. J Clin Oncol 2009; 27: 2253-2260.
23. Rekhtman N, Paik PK, Arcila ME etal. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res 2012; 18: 1167-1176.
24. Ho HL, Chang FP, Ma HH etal. Molecular diagnostic algorithm for epidermal growth factor receptor mutation detection in Asian lung adenocarcinomas: comprehensive analyses of 445 Taiwanese patients with immunohistochemistry, PCR-direct sequencing and Scorpion/ARMS methods. Respirology 2013; 18: 1261-1270.
25. Schwitter M, Rodriguez R, Schneider T, Kluckert T, Brutsche M, Fruh M. Epidermal growth factor receptor mutation in a patient with squamous cell carcinoma of the lung: who should be tested? Case Rep Oncol 2013; 6: 263-268.
26. Brugger W, Triller N, Blasinska-Morawiec M etal. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 2011; 29: 4113-4120.
27. Yatabe Y, Matsuo K, Mitsudomi T. Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol 2011; 29: 2972-2977.
28. Ramalingam SS, Blackhall F, Krzakowski M etal. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2012; 30: 3337-3344.
29. Garassino MC, Martelli O, Broggini M etal. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol 2013; 14: 981-988.